DK2402450T3 - Fremgangsmåder til opnåelse af rekombinante proteiner med reducerede LacdiNac-strukturer - Google Patents

Fremgangsmåder til opnåelse af rekombinante proteiner med reducerede LacdiNac-strukturer

Info

Publication number
DK2402450T3
DK2402450T3 DK11158266.4T DK11158266T DK2402450T3 DK 2402450 T3 DK2402450 T3 DK 2402450T3 DK 11158266 T DK11158266 T DK 11158266T DK 2402450 T3 DK2402450 T3 DK 2402450T3
Authority
DK
Denmark
Prior art keywords
epo
glycans
cell
average
linked
Prior art date
Application number
DK11158266.4T
Other languages
English (en)
Inventor
Dirk Jan Elbertus Opstelten
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36021744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2402450(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/026,518 external-priority patent/US20050164386A1/en
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK2402450T3 publication Critical patent/DK2402450T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK11158266.4T 2004-12-30 2005-12-28 Fremgangsmåder til opnåelse af rekombinante proteiner med reducerede LacdiNac-strukturer DK2402450T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/026,518 US20050164386A1 (en) 1999-04-15 2004-12-30 Overexpression of enzymes involved in post-translational protein modifications in human cells
US11/102,073 US7297680B2 (en) 1999-04-15 2005-04-08 Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
EP05850503A EP1831381B1 (en) 2004-12-30 2005-12-28 Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus e1a protein, and proteins obtained thereby

Publications (1)

Publication Number Publication Date
DK2402450T3 true DK2402450T3 (da) 2013-10-07

Family

ID=36021744

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11158266.4T DK2402450T3 (da) 2004-12-30 2005-12-28 Fremgangsmåder til opnåelse af rekombinante proteiner med reducerede LacdiNac-strukturer

Country Status (10)

Country Link
US (2) US7297680B2 (da)
EP (2) EP1831381B1 (da)
KR (1) KR101319733B1 (da)
CN (1) CN102653772B (da)
AT (1) ATE513919T1 (da)
AU (1) AU2005321246B2 (da)
CA (2) CA2592100C (da)
DK (1) DK2402450T3 (da)
SG (1) SG158185A1 (da)
WO (1) WO2006070011A1 (da)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
CA2465007C (en) * 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
KR100979025B1 (ko) * 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US8524477B2 (en) * 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
EP1623023B1 (en) * 2003-05-09 2008-11-12 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
US7642078B2 (en) * 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
CA2647524C (en) 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20090208480A1 (en) * 2006-08-04 2009-08-20 Yue Huang Long half-life recombinant butyrylcholinesterase
WO2008127359A2 (en) * 2006-10-10 2008-10-23 University Of Wyoming An insect cell line for production of recombinant glycoproteins with sulfated complex n-glycans
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
EP2111412A2 (en) 2007-02-02 2009-10-28 Amgen, Inc Hepcidin and hepcidin antibodies
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
MX2010008096A (es) 2008-01-25 2010-09-22 Amgen Inc Anticuerpos de ferroportina y metodos de uso.
MX2010011717A (es) 2008-05-01 2010-11-30 Amgen Inc Anticuerpos anti-hepcidina y metodos de uso.
US9012176B2 (en) * 2008-09-19 2015-04-21 Agency For Science, Technology And Research (A*Star) Chinese hamster ovary cell lines
CN102215869B (zh) 2008-11-13 2015-05-13 通用医疗公司 用于通过调整bmp-6来调节铁稳态的方法和组合物
KR101640962B1 (ko) * 2009-04-23 2016-07-19 크루셀 홀란드 비.브이. 재조합 인간 알파1-항트립신
EP2490957B1 (en) 2009-10-23 2016-11-23 Amgen, Inc Vial adapter and system
JP2013526840A (ja) 2009-12-21 2013-06-27 ファーマシーネ，インコーポレイテッド 組み換えブチリルコリンエステラーゼおよびその切断型
BR112012031121B1 (pt) 2010-06-07 2022-09-27 Amgen Inc Dispositivo de distribuição de drogas, kit e método de operar um dispositivo de distribuição de droga utilizável
MX341790B (es) 2011-03-31 2016-09-02 Amgen Inc Adaptador de viales y sistema.
SI2699293T1 (sl) 2011-04-20 2019-05-31 Amgen Inc. Avtoinjekcijski aparat
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR102222187B1 (ko) 2011-10-14 2021-03-03 암젠 인크 주사기 및 어셈블리 방법
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20150290390A1 (en) 2012-11-21 2015-10-15 Amgen Inc. Drug delivery device
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
BR112015022123B1 (pt) 2013-03-15 2022-08-09 Intrinsic Lifesciences, Llc Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
TWI639453B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
EP2968760B1 (en) 2013-03-15 2024-01-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
EP3831427A1 (en) 2013-03-22 2021-06-09 Amgen Inc. Injector and method of assembly
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
PL3060275T3 (pl) 2013-10-24 2019-12-31 Amgen Inc. Wstrzykiwacz i sposób montażu
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
CN103820514B (zh) * 2014-03-10 2017-10-31 深圳赛保尔生物药业有限公司 一种高效生产促红细胞生成素的方法
EP3139977B1 (en) 2014-05-07 2021-02-17 Amgen Inc. Autoinjector with shock reducing elements
IL281354B2 (en) 2014-06-03 2024-06-01 Amgen Inc Devices and methods to assist the user of a drug delivery device
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
JP6766040B2 (ja) 2014-10-14 2020-10-07 アムジエン・インコーポレーテツド 視覚および可聴インジケータを備える薬剤注射装置
EP3233159B1 (en) 2014-12-19 2020-03-04 Amgen Inc. Drug delivery device with live button or user interface field
WO2016100781A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with proximity sensor
AU2016220141B2 (en) 2015-02-17 2018-07-12 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
ES2814287T3 (es) 2016-03-15 2021-03-26 Amgen Inc Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
JP7309363B2 (ja) 2016-05-13 2023-07-18 アムジエン・インコーポレーテツド バイアル・スリーブ組立体
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
CA3048520A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
KR20240005194A (ko) 2017-03-09 2024-01-11 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
ES2959935T3 (es) 2017-03-28 2024-02-29 Amgen Inc Sistema y método de vástago de émbolo y conjunto de jeringa
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
US11541183B2 (en) 2017-06-22 2023-01-03 Amgen Inc. Device activation impact/shock reduction
US11395880B2 (en) 2017-06-23 2022-07-26 Amgen Inc. Electronic drug delivery device
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
IL271173B2 (en) 2017-07-21 2024-04-01 Amgen Inc Gas permeable sealing element for drug container and methods of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
IL273323B1 (en) 2017-10-09 2024-06-01 Amgen Inc Drug delivery device with drive assembly and related assembly method
EP3703779A1 (en) 2017-11-03 2020-09-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
JP2021501616A (ja) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド 配置及び流量検出を備える薬物送達デバイス
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
EP3706826A1 (en) 2017-11-10 2020-09-16 Amgen Inc. Plungers for drug delivery devices
AU2018368338A1 (en) 2017-11-16 2020-04-09 Amgen Inc. Autoinjector with stall and end point detection
CA3079540A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023444A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
AU2019347710A1 (en) 2018-09-24 2021-02-04 Amgen Inc. Interventional dosing systems and methods
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
MX2021003492A (es) 2018-10-02 2021-06-18 Amgen Inc Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna.
MX2021003491A (es) 2018-10-05 2021-06-18 Amgen Inc Dispositivo de administracion de farmacos con indicador de dosis.
EA202191038A1 (ru) 2018-10-15 2021-07-06 Эмджен Инк. Способ платформенной сборки для устройства доставки лекарственного средства
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
EP3873566A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
AU2020263289A1 (en) 2019-04-24 2021-09-16 Amgen Inc. Syringe sterilization verification assemblies and methods
AU2020337250A1 (en) 2019-08-23 2022-03-03 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
MX2023013640A (es) 2021-05-21 2023-11-30 Amgen Inc Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.
SE2230210A1 (en) * 2022-06-24 2023-12-25 Fixell Biotech Ab High eukaryotic cell density transient transfection process for manufacturing of recombinant viral vectors
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
GB8900483D0 (en) 1989-01-10 1989-03-08 Celltech Ltd Recombinant dna method
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
ES2100953T3 (es) 1991-08-01 1997-07-01 Fond Nat Transfusion Sanguine Expresion en lineas linfoblastoides humanas no tumorales con un vector integrante.
US5518913A (en) 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
US5384249A (en) 1991-12-17 1995-01-24 Kyowa Hakko Kogyo Co., Ltd. α2→3 sialyltransferase
US5426178A (en) * 1993-03-31 1995-06-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis of anti-inflammatory compounds, and novel trisaccharides useful in the synthesis of anti-inflammatory compounds
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US5733782A (en) 1993-10-25 1998-03-31 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5789247A (en) 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
US5610043A (en) 1994-04-28 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
CA2235629A1 (en) 1995-11-13 1997-05-22 Takara Shuzo Co., Ltd. Method for gene transfer into target cells with retrovirus
US5681597A (en) * 1996-02-06 1997-10-28 Liquid Container L.P. Vacuum conveyor picker for blow bottle container
US5856292A (en) 1996-04-08 1999-01-05 Colgate Palmolive Company Light duty liquid cleaning compositions
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
WO1998018926A1 (en) 1996-10-25 1998-05-07 G.D. Searle & Co. Circularly permuted erythropoietin receptor agonists
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5865382A (en) * 1997-01-24 1999-02-02 Beloit Technologies, Inc. Protection system for a wood chip destructuring device
JP2000509614A (ja) 1997-03-04 2000-08-02 バクスター インターナショナル インコーポレイテッド アデノウイルスｅ１−相補性細胞系
CA2221819A1 (en) 1997-03-27 1998-09-27 Thomas A. Gigliatti Insect expression vectors
PT1012319E (pt) 1997-03-27 2005-06-30 Univ British Columbia Vectores de expressao de insectos
JP4541539B2 (ja) 1997-07-23 2010-09-08 ロシュ ダイアグノスティックス ゲーエムベーハー 内因性遺伝子活性化によるエリスロポエチンの製造
AR022358A1 (es) 1997-12-03 2002-09-04 Roche Olivier Una composicion de epo, un procedimiento para su obtencion, un preparado farmaceutico que la contiene y un procedimiento para aumentar la actividadespecifica de una composicion de epo
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP2002518010A (ja) 1998-06-16 2002-06-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９４個のヒト分泌タンパク質
EA004766B1 (ru) 1999-04-13 2004-08-26 Дзе Кеннет С. Уоррен Инститьют, Инк. Модуляция функции возбуждаемых тканей за счет периферического введения эритропоэтина
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) * 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
EP1533380B1 (en) * 1999-04-15 2009-11-04 Crucell Holland B.V. Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US6506598B1 (en) 1999-04-26 2003-01-14 Genentech, Inc. Cell culture process
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
WO2001088117A2 (en) * 2000-05-12 2001-11-22 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
EP1184458A1 (en) 2000-08-28 2002-03-06 U-BISys B.V. Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
EP1256803A1 (en) * 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
CA2465007C (en) 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
AU2002225509A1 (en) 2001-12-07 2003-06-17 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
SI1456238T1 (sl) 2001-12-17 2008-08-31 Crucell Holland Bv Proizvodnja f(ab)2 fragmentov v sesalskih celicah
AU2003206251B2 (en) * 2002-01-09 2008-03-13 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
NZ537306A (en) 2002-07-01 2008-11-28 Kenneth S Warren Inst Inc Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
US7332303B2 (en) 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
EP1623023B1 (en) * 2003-05-09 2008-11-12 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
US7642078B2 (en) * 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby

Also Published As

Publication number Publication date
SG158185A1 (en) 2010-01-29
EP1831381B1 (en) 2011-06-22
KR20070110841A (ko) 2007-11-20
US7833753B2 (en) 2010-11-16
CN102653772A (zh) 2012-09-05
CA2877364A1 (en) 2006-07-06
KR101319733B1 (ko) 2013-10-23
US7297680B2 (en) 2007-11-20
AU2005321246B2 (en) 2011-04-14
US20050181359A1 (en) 2005-08-18
WO2006070011A1 (en) 2006-07-06
AU2005321246A1 (en) 2006-07-06
CA2592100C (en) 2015-03-17
CN102653772B (zh) 2014-04-02
ATE513919T1 (de) 2011-07-15
EP2402450A1 (en) 2012-01-04
US20070298464A1 (en) 2007-12-27
EP1831381A1 (en) 2007-09-12
CA2592100A1 (en) 2006-07-06
EP2402450B1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
DK2402450T3 (da) Fremgangsmåder til opnåelse af rekombinante proteiner med reducerede LacdiNac-strukturer
JP5076084B2 (ja) 組み換えタンパク質の大量生産のための新規ベクターおよび発現細胞株と、これを用いた組み換えタンパク質の生産方法
Amann et al. Glyco-engineered CHO cell lines producing alpha-1-antitrypsin and C1 esterase inhibitor with fully humanized N-glycosylation profiles
JP5925407B2 (ja) ヒト細胞系における組換えヒトタンパク質の無血清安定トランスフェクションおよび製造
DK1658365T3 (da) Fremgangsmåde til genkloning af produktionsceller
WO2007015848A3 (en) Improved methods and compositions for increasing longevity and protein yield from a cell culture
WO2006042158A3 (en) Methods and compositions for improving recombinant protein production
RO120267B1 (ro) Metodă de control a procesului de sialilare a proteinelor obţinute în culturi de celule animale
WO2003048364A3 (en) Ovomucoid promoter and methods of use
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
BR9908018A (pt) Adenovìrus modificado contendo uma proteìna de substituição de fibra
JP4809227B2 (ja) タンパク質の産生に使用するためのリーダー配列
Tavernier et al. Expression of human and murine interleukin-5 in eukaryotic systems
Liu et al. Production of mouse granulocyte‐macrophage colony‐stimulating factor by gateway technology and transgenic rice cell culture
Stutz Advances and applications of capillary electromigration methods in the analysis of therapeutic and diagnostic recombinant proteins–A Review
WO2006060089A3 (en) Novel methods for producing adenoviral vector preparations with reduced replication-competent adenovirus contamination and novel adenoviral vectors and preparations
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
JP2016535071A5 (da)
JP2005058111A (ja) 糖鎖修飾制御方法
Salgado et al. Post-translational modification of a chimeric EPO-Fc hormone is more important than its molecular size in defining its in vivo hematopoietic activity
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
WO2000015772A3 (en) Recombinant protein production in urine
EP4222275A1 (en) Cell culture process for producing rsv f protein
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
US20210262000A1 (en) Glycosylation of proteins